EdgarLookup

PHOTRONICS INC — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that PHOTRONICS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
94.3%
Profit Margin
Net income ÷ revenue
7.6%
Return on Assets
Net income ÷ assets
0.18x
Debt-to-Equity
Total liabilities ÷ equity
+6.1%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2018 Oct 31, 2018 $144.66M Dec 21, 2018
FY2018 Jul 29, 2018 $136.39M Dec 21, 2018
FY2018 Apr 29, 2018 $130.78M Dec 21, 2018
FY2018 Jan 28, 2018 $123.45M Dec 21, 2018
FY2018 Oct 29, 2017 $120.97M Dec 21, 2018
FY2018 Jul 30, 2017 $111.58M Dec 21, 2018
FY2018 Apr 30, 2017 $108.30M Dec 21, 2018
FY2018 Jan 29, 2017 $109.83M Dec 21, 2018
FY2018 Oct 30, 2016 $483.46M Dec 21, 2018

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $849.29M Dec 17, 2025
FY2025 Oct 31, 2024 $866.95M Dec 17, 2025
FY2025 Oct 31, 2023 $892.08M Dec 17, 2025
FY2024 Oct 31, 2022 $824.55M Dec 19, 2024
FY2023 Oct 31, 2021 $663.76M Dec 26, 2023
FY2020 Oct 31, 2020 $149.29M Jan 15, 2021
FY2020 Aug 2, 2020 $157.90M Jan 15, 2021
FY2020 May 3, 2020 $142.77M Jan 15, 2021
FY2020 Feb 2, 2020 $159.74M Jan 15, 2021
FY2020 Oct 31, 2019 $156.26M Jan 15, 2021

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $299.83M Dec 17, 2025
FY2025 Oct 31, 2024 $315.95M Dec 17, 2025
FY2025 Oct 31, 2023 $336.16M Dec 17, 2025
FY2024 Oct 31, 2022 $294.21M Dec 19, 2024
FY2023 Oct 31, 2021 $167.04M Dec 26, 2023
FY2020 Oct 31, 2020 $31.89M Jan 15, 2021
FY2020 Aug 2, 2020 $37.73M Jan 15, 2021
FY2020 May 3, 2020 $30.43M Jan 15, 2021
FY2020 Feb 2, 2020 $34.60M Jan 15, 2021
FY2020 Oct 31, 2019 $38.16M Jan 15, 2021

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $136.41M Dec 17, 2025
FY2025 Oct 31, 2024 $130.69M Dec 17, 2025
FY2025 Oct 31, 2023 $125.49M Dec 17, 2025
FY2024 Oct 31, 2022 $118.79M Dec 19, 2024
FY2023 Oct 31, 2021 $55.45M Dec 26, 2023
FY2020 Oct 31, 2020 $6.46M Jan 15, 2021
FY2020 Aug 2, 2020 $10.78M Jan 15, 2021
FY2020 May 3, 2020 $6.28M Jan 15, 2021
FY2020 Feb 2, 2020 $10.30M Jan 15, 2021
FY2020 Oct 31, 2019 $9.70M Jan 15, 2021

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $208.16M Dec 17, 2025
FY2025 Oct 31, 2024 $221.52M Dec 17, 2025
FY2025 Oct 31, 2023 $253.05M Dec 17, 2025
FY2024 Oct 31, 2022 $211.87M Dec 19, 2024
FY2023 Oct 31, 2021 $94.55M Dec 26, 2023
FY2022 Oct 31, 2020 $63.93M Dec 23, 2022
FY2021 Oct 31, 2019 $52.12M Dec 17, 2021
FY2020 Oct 31, 2018 $65.63M Jan 15, 2021
FY2019 Oct 29, 2017 $31.87M Dec 23, 2019
FY2018 Oct 30, 2016 $52.48M Dec 21, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $15.80M Dec 17, 2025
FY2025 Oct 31, 2024 $16.58M Dec 17, 2025
FY2025 Oct 31, 2023 $13.65M Dec 17, 2025
FY2024 Oct 31, 2022 $18.34M Dec 19, 2024
FY2023 Oct 31, 2021 $18.49M Dec 26, 2023
FY2022 Oct 31, 2020 $17.14M Dec 23, 2022
FY2021 Oct 31, 2019 $16.39M Dec 17, 2021
FY2020 Oct 31, 2018 $14.48M Jan 15, 2021
FY2019 Oct 29, 2017 $15.86M Dec 23, 2019
FY2018 Oct 30, 2016 $21.65M Dec 21, 2018

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $75.63M Dec 17, 2025
FY2025 Oct 31, 2024 $77.76M Dec 17, 2025
FY2025 Oct 31, 2023 $69.46M Dec 17, 2025
FY2024 Oct 31, 2022 $63.99M Dec 19, 2024
FY2023 Oct 31, 2021 $57.53M Dec 26, 2023
FY2022 Oct 31, 2020 $53.58M Dec 23, 2022
FY2021 Oct 31, 2019 $52.33M Dec 17, 2021
FY2020 Oct 31, 2018 $51.40M Jan 15, 2021
FY2019 Oct 29, 2017 $43.59M Dec 23, 2019
FY2018 Oct 30, 2016 $44.58M Dec 21, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $247.80M Dec 17, 2025
FY2025 Oct 31, 2024 $261.44M Dec 17, 2025
FY2025 Oct 31, 2023 $302.18M Dec 17, 2025
FY2024 Oct 31, 2022 $275.19M Dec 19, 2024
FY2023 Oct 31, 2021 $150.77M Dec 26, 2023
FY2022 Oct 31, 2020 $143.05M Dec 23, 2022
FY2021 Oct 31, 2019 $68.39M Dec 17, 2021
FY2020 Oct 31, 2018 $130.57M Jan 15, 2021
FY2019 Oct 29, 2017 $96.83M Dec 23, 2019
FY2018 Oct 30, 2016 $122.14M Dec 21, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $188.14M Dec 17, 2025
FY2025 Oct 31, 2024 $130.94M Dec 17, 2025
FY2025 Oct 31, 2023 $131.30M Dec 17, 2025
FY2024 Oct 31, 2022 $112.34M Dec 19, 2024
FY2023 Oct 31, 2021 $109.10M Dec 26, 2023
FY2022 Oct 31, 2020 $70.82M Dec 23, 2022
FY2021 Oct 31, 2019 $178.38M Dec 17, 2021
FY2020 Oct 31, 2018 $92.59M Jan 15, 2021
FY2019 Oct 29, 2017 $91.97M Dec 23, 2019
FY2018 Oct 30, 2016 $50.15M Dec 21, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $1.80B Dec 17, 2025
FY2025 Oct 31, 2024 $1.71B Dec 17, 2025
FY2024 Oct 31, 2023 $1.53B Dec 19, 2024
FY2023 Oct 31, 2022 $1.32B Dec 26, 2023
FY2022 Oct 31, 2021 $1.29B Dec 23, 2022
FY2021 Oct 31, 2020 $1.19B Dec 17, 2021
FY2020 Oct 31, 2019 $1.12B Jan 15, 2021
FY2019 Oct 31, 2018 $1.11B Dec 23, 2019
FY2018 Oct 29, 2017 $1.02B Dec 21, 2018
FY2017 Oct 30, 2016 $987.99M Dec 20, 2017

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $207.23M Dec 17, 2025
FY2025 Oct 31, 2024 $231.30M Dec 17, 2025
FY2024 Oct 31, 2023 $250.61M Dec 19, 2024
FY2023 Oct 31, 2022 $253.74M Dec 26, 2023
FY2022 Oct 31, 2021 $293.64M Dec 23, 2022
FY2021 Oct 31, 2020 $225.92M Dec 17, 2021
FY2020 Oct 31, 2019 $207.57M Jan 15, 2021
FY2019 Oct 31, 2018 $205.44M Dec 23, 2019
FY2018 Oct 29, 2017 $155.50M Dec 21, 2018
FY2017 Oct 30, 2016 $162.51M Dec 20, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $1.17B Dec 17, 2025
FY2025 Oct 31, 2024 $1.12B Dec 17, 2025
FY2024 Oct 31, 2023 $975.01M Dec 19, 2024
FY2023 Oct 31, 2022 $831.53M Dec 26, 2023
FY2022 Oct 31, 2021 $823.69M Dec 23, 2022
FY2021 Oct 31, 2020 $804.96M Dec 17, 2021
FY2020 Oct 31, 2019 $769.89M Jan 15, 2021
FY2019 Oct 31, 2018 $759.67M Dec 23, 2019
FY2018 Oct 29, 2017 $744.56M Dec 21, 2018
FY2017 Oct 30, 2016 $710.36M Dec 20, 2017

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $772.20M Dec 17, 2025
FY2025 Oct 31, 2024 $691.81M Dec 17, 2025
FY2024 Oct 31, 2023 $561.12M Dec 19, 2024
FY2023 Oct 31, 2022 $435.63M Dec 26, 2023
FY2022 Oct 31, 2021 $317.85M Dec 23, 2022
FY2021 Oct 31, 2020 $279.04M Dec 17, 2021
FY2020 Oct 31, 2019 $253.92M Jan 15, 2021
FY2019 Oct 31, 2018 $231.45M Dec 23, 2019
FY2018 Oct 29, 2017 $189.39M Dec 21, 2018
FY2017 Oct 30, 2016 $176.26M Dec 20, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 $492.26M Dec 17, 2025
FY2025 Oct 31, 2024 $598.49M Dec 17, 2025
FY2025 Oct 31, 2023 $499.29M Dec 17, 2025
FY2024 Oct 31, 2022 $319.68M Dec 19, 2024
FY2023 Oct 31, 2021 $276.67M Dec 26, 2023
FY2022 Oct 31, 2020 $278.67M Dec 23, 2022
FY2021 Oct 31, 2019 $206.53M Dec 17, 2021
FY2019 Oct 31, 2018 $329.28M Dec 23, 2019
FY2018 Oct 29, 2017 $308.02M Dec 21, 2018
FY2018 Oct 30, 2016 $314.07M Dec 21, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2020 Oct 31, 2020 $63.95M Jan 15, 2021
FY2020 Oct 31, 2019 $44.03M Jan 15, 2021
FY2019 Oct 31, 2018 $57.45M Dec 23, 2019

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 2 Dec 17, 2025
FY2025 Oct 31, 2024 2 Dec 17, 2025
FY2025 Oct 31, 2023 2 Dec 17, 2025
FY2024 Oct 31, 2022 1 Dec 19, 2024
FY2023 Oct 31, 2021 0 Dec 26, 2023
FY2020 Oct 31, 2020 0 Jan 15, 2021
FY2020 Aug 2, 2020 0 Jan 15, 2021
FY2020 May 3, 2020 0 Jan 15, 2021
FY2020 Feb 2, 2020 0 Jan 15, 2021
FY2020 Oct 31, 2019 0 Jan 15, 2021

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 2 Dec 17, 2025
FY2025 Oct 31, 2024 2 Dec 17, 2025
FY2025 Oct 31, 2023 2 Dec 17, 2025
FY2024 Oct 31, 2022 1 Dec 19, 2024
FY2023 Oct 31, 2021 0 Dec 26, 2023
FY2020 Oct 31, 2020 0 Jan 15, 2021
FY2020 Aug 2, 2020 0 Jan 15, 2021
FY2020 May 3, 2020 0 Jan 15, 2021
FY2020 Feb 2, 2020 0 Jan 15, 2021
FY2020 Oct 31, 2019 0 Jan 15, 2021

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Oct 31, 2025 57.63M Dec 17, 2025
FY2025 Oct 31, 2024 61.95M Dec 17, 2025
FY2024 Oct 31, 2023 61.31M Dec 19, 2024
FY2023 Oct 31, 2022 60.79M Dec 26, 2023
FY2022 Oct 31, 2021 60.02M Dec 23, 2022
FY2021 Oct 31, 2020 63.14M Dec 17, 2021
FY2020 Oct 31, 2019 65.60M Jan 15, 2021
FY2019 Oct 31, 2018 67.14M Dec 23, 2019
FY2018 Oct 29, 2017 68.67M Dec 21, 2018
FY2017 Oct 30, 2016 68.08M Dec 20, 2017